Subsequent work also revealed that the oncometabolite produced as a result of the IDH1/2 mutation, 2-hydroxyglutarate (2-HG), can be detected by magnetic resonance spectroscopy [15,16,17], further solidifying the importance of this particular mutation, and molecular diagnostic techniques in general, in the future of glioma diagnosis. This evidence concerns the gene IDH1 and glioma.